Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Quality of Life in Long-Term Testicular Cancer Survivors With Compensated Leydig Cell Dysfunction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Preorchiectomy Leydig Cell Dysfunction in Patients With Testicular Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prostate Artery Embolization for Lower Urinary Tract Symptoms in Men Unfit for Surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Active surveillance (AS) and radical prostatectomy (RP) are both accepted treatments for men with favorable-risk localized prostate cancer (PCa) (ie, clinical tumor category 1-2b, Gleason Grade Group 1-2, and prostate-specific antigen < 20 ng/mL). However, head-to-head studies comparing oncologic outcomes and survival between these 2 treatment strategies are warranted. The objective of this study was to compare the use of prostate cancer treatments and PCa death in men managed on AS and men who underwent immediate RP.

PATIENTS AND METHODS: This was an observational study including 647 men on AS and 647 men treated with RP propensity score matched. We examined the 10-year cumulative incidence of salvage radiotherapy, hormonal therapy, castration-resistant PCa, and PCa death.

RESULTS: The 10-year curative treatment-free survival for men on AS was 61% (95% confidence interval [CI], 57%-65%). No differences in use of salvage radiotherapy (AS, 2.7%; 95% CI, 1.4%-4.1% vs. RP 5.4%; 95% CI, 3.4%-7.3%), hormonal therapy (AS, 6.9%; 95% CI, 4.4%-9.4% vs. RP, 4.1%; 95% CI, 2.5%-5.6%), developing castration-resistant PCa (AS, 1.7%; 95% CI, 0.5%-2.9% vs. RP, 2.0%; 95% CI, 0.7%-3.4%), or cumulative PCa mortality (AS, 0.4%; 95% CI, 0%-1.0% vs. RP, 0.5%; 95% CI, 0%-1.5%) were observed between the treatment strategies. The main limitation was the non-random allocation to treatment strategy.

CONCLUSION: In this observational study on men with favorable-risk localized PCa, we found similar PCa mortality at 10 years between men on AS and men who underwent immediate RP. Moreover, there were no differences in the use of PCa therapies between the groups. Our study supports active surveillance as a treatment strategy for men with favorable-risk localized PCa.

OriginalsprogEngelsk
TidsskriftClinical Genitourinary Cancer
Vol/bind17
Udgave nummer4
Sider (fra-til)e814-e821
ISSN1938-0682
DOI
StatusUdgivet - 1 aug. 2019

Bibliografisk note

Copyright © 2019 Elsevier Inc. All rights reserved.

ID: 57420011